نبذة مختصرة : The purpose and objectives: The aim of this study was to evaluate the potential hospital-acquired pneumonia pathogens, as well as the dynamics of antibiotic resistance in intensive care units in 2015. To achieve this, four objectives were determined: to identify the most common potential nosocomial pneumonia pathogens in LSMUK central, neurosurgical and cardiosurgical intensive care units, compare the spectrum of potential pathogens between intensive care units, to assess the antibiotic resistance amongthe most common hospital-acquired pneumonia pathogens and to compare the antibiotic resistance of these potential pathogens between intensive care units. Test methods: The study was carried out by retrospectively examining microbiological samples of the lower respiratory tract secretion from patients who were treated in Lithuanian Health Sciences University Hospital intensive care units in 2015. Microorganisms that colonised lower respiratory tract were identified and their antibiotic resistance was determined. Results and conclusions: for ICU patients most often pathogens wereEnterobacteriaceaespp. (35.0 per cent). Other common causative agents were P. aeruginosa, Acinetobacter spp. and S. aureus (together accounting for 43 per cent). From patients in the central ICU Acinetobacter spp. and Candida spp. were isolated more often, while S. aureus was more frequent in neurosurgical ICU. P. aeruginosa. Was more frequent in cardiosurgical ICU. Acinetobacter spp. were resistant to most antibiotics, they were the most sensitive to tigecycline (41.1 percent) and cefoperazone-sublactam (38.0 percent). Enterobacteriaceae spp. were sensitive to most antibiotics and were the most resistant to cefotaxim (34,9 proc.) and cefuroxim (46,7 proc.). P. aeruginosa was sensitive to most antibiotics, it was the most sensitive to antipseudomonic penicillins, cephalosporins, and aminoglycosides (sensitivity from 71 to 94 percent). P. aeruginosa was the least sensitive to carbapenems (64-66 percent.). S. aureus was sensitive to oxacillin ...
No Comments.